Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 770 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Brain Neoplasm, Malignant Clear all
Active, not recruiting Phase 1 Interventional

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

NCT04459273
View directory record Official record
Conditions
Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site
Interventions
Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG
Procedure · Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 23, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors

NCT02197169
View directory record Official record
Conditions
Glioblastoma or Gliosarcoma
Interventions
Single intratumoral injection of DNX-2401, Interferon-gamma
Drug
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Jul 23, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Tabectedin to Treat Children and Adolescents With Cancer

NCT01453283
View directory record Official record
Conditions
Solid Tumors
Interventions
Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 1:14 AM EDT
Completed Early Phase 1 Interventional

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

NCT00424242
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jul 23, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Fluorescence Guided Resection of Brain Tumors

NCT00870779
View directory record Official record
Conditions
Brain Tumors
Interventions
5-aminolevulinic acid
Drug
Lead sponsor
David W. Roberts
Other
Eligibility
21 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Jul 23, 2026, 1:14 AM EDT
Recruiting Phase 3 Interventional

Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases

NCT03741673
View directory record Official record
Conditions
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 23, 2026, 1:14 AM EDT
Terminated Phase 1 Interventional

Study of Immunotoxin, MR1-1

NCT01009866
View directory record Official record
Conditions
Supratentorial Malignant Brain Tumor
Interventions
MR1-1
Biological
Lead sponsor
Darell D. Bigner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Jul 23, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Results available

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

NCT02323880
View directory record Official record
Conditions
Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, WHO Grade 3 Glioma
Interventions
Pharmacological Study, Selinexor
Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jul 23, 2026, 1:14 AM EDT
Terminated Phase 1 Interventional

Enzastaurin to Treat Recurrent Brain Tumor

NCT00108056
View directory record Official record
Conditions
Glioma
Interventions
Enzastaurin (LY317615) monohydronchloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Jul 23, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

NCT01257594
View directory record Official record
Conditions
Brain Cancer
Interventions
erlotinib, Cytoreductive Surgery
Drug · Procedure
Lead sponsor
Andrew B Lassman, MD
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jul 23, 2026, 1:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases

NCT00026494
View directory record Official record
Conditions
Metastatic Cancer
Interventions
temozolomide, vinorelbine tartrate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Jul 23, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

NCT00671970
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Bevacizumab and Erlotinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2013 · Synced Jul 23, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

NCT00613054
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Zactima, Gleevec, Hydroxyurea
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Jul 23, 2026, 1:14 AM EDT
Terminated Phase 1 Interventional

VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma

NCT00516282
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
CLORETAZINE, temozolomide
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Jul 23, 2026, 1:14 AM EDT
Active, not recruiting Not applicable Interventional

PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

NCT01266096
View directory record Official record
Conditions
Newly Diagnosed or Recurrent Metastatic Melanoma Patients, Malignant Brain Tumors
Interventions
PET scan with 124I-cRGDY-PEG-dots
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 23, 2026, 1:14 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer

NCT02128373
View directory record Official record
Conditions
Stage IV Lung Cancer, Malignant Brain Tumor
Interventions
Usual care, computer-assisted intervention, Distress Thermometer, Profile of Mood States (POMS-B), Quality of Life: Functional Assessment in Cancer Therapy - (FACT), Tension-Anxiety Subscale
Procedure · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2015 · Synced Jul 23, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

NCT01441596
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
Vinorelbine, Investigator's choice of treatment, afatinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Jul 23, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer

NCT01048008
View directory record Official record
Conditions
Advanced Cancer, Brain Involvement
Interventions
DM-CHOC-PEN
Drug
Lead sponsor
DEKK-TEC, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Jul 23, 2026, 1:14 AM EDT
Recruiting No phase listed Interventional

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

NCT00935090
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
3'-deoxy-3'-[18F]fluorothymidine
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jul 23, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma

NCT00462982
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Jul 23, 2026, 1:14 AM EDT
Terminated Phase 2 Interventional

Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors

NCT00848523
View directory record Official record
Conditions
Recurrent Malignant Gliomas
Interventions
Panobinostat
Drug
Lead sponsor
Neurological Surgery, P.C.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Commack, New York • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2010 · Synced Jul 23, 2026, 1:14 AM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

NCT07493447
View directory record Official record
Conditions
Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Interventions
Panitumumab-IRDye800
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 23, 2026, 1:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Development of MR Spectroscopy and Imaging in Brain Cancers

NCT02731521
View directory record Official record
Conditions
Malignant Gliomas, Astrocytomas, Oligodendrogliomas
Interventions
3 Tesla Scanning, 7 Tesla Scanning
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Jul 23, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

NCT00613132
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Gleevec, RAD001, and Hydroxyurea
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Jul 23, 2026, 1:14 AM EDT